27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.

ETTX Insider Trading (Entasis Therapeutics)

Insider Ownership Percentage: 6.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $50,188.27

Entasis Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Entasis Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Entasis Therapeutics Share Price & Price History

Current Price: $2.19
Price Change: Price Decrease of -0.01 (-0.45%)
As of 07/1/2022 04:58 PM ET

This chart shows the closing price history over time for ETTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.

Entasis Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/19/2021Elizabeth M. KeileyGeneral CounselSell3,759$3.19$11,991.21View SEC Filing Icon  
10/19/2021Manoussos PerrosInsiderSell11,974$3.19$38,197.06View SEC Filing Icon  
6/11/2021Innoviva, Inc.Major ShareholderBuy6,268,975$2.00$12,537,950.00View SEC Filing Icon  
5/3/2021Innoviva, Inc.Major ShareholderBuy3,731,025$2.00$7,462,050.00View SEC Filing Icon  
9/1/2020Innoviva, Inc.Major ShareholderBuy4,672,897$2.68$12,523,363.96View SEC Filing Icon  
6/11/2020Innoviva, Inc.Major ShareholderBuy12,677,490$2.50$31,693,725.00View SEC Filing Icon  
See Full Table
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.

SEC Filings (Institutional Ownership Changes) for Entasis Therapeutics (NASDAQ:ETTX)

6.91% of Entasis Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ETTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Entasis Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/18/2022Gabelli Funds LLC59,100$0.11M0.0%N/A0.124%Search for SEC Filing on Google Icon
5/18/2022GABELLI & Co INVESTMENT ADVISERS INC.40,900$76K0.0%N/A0.085%Search for SEC Filing on Google Icon
5/13/2022GABELLI & Co INVESTMENT ADVISERS INC.40,900$76K0.0%N/A0.085%Search for SEC Filing on Google Icon
5/13/2022Gabelli Funds LLC59,100$0.11M0.0%N/A0.124%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.483,723$0.91M0.0%+7.5%1.011%Search for SEC Filing on Google Icon
2/10/2022Acadian Asset Management LLC55,813$0.12M0.0%+172.0%0.117%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Advisers LP229,000$0.77M0.0%+40.5%0.481%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Investments LP186,230$0.62M0.0%+13.4%0.391%Search for SEC Filing on Google Icon
11/15/2021Alberta Investment Management Corp65,000$0.22M0.0%-50.0%0.136%Search for SEC Filing on Google Icon
11/12/2021Renaissance Technologies LLC312,545$1.04M0.0%-20.2%0.656%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.26,619$89K0.0%-18.8%0.056%Search for SEC Filing on Google Icon
8/17/2021Bridgeway Capital Management LLC110,000$0.29M0.0%-8.3%0.233%Search for SEC Filing on Google Icon
8/16/2021Alberta Investment Management Corp130,000$0.35M0.0%N/A0.275%Search for SEC Filing on Google Icon
8/16/2021Occudo Quantitative Strategies LP23,058$62K0.0%-20.6%0.049%Search for SEC Filing on Google Icon
8/16/2021State Street Corp39,205$0.11M0.0%N/A0.083%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC391,629$1.05M0.0%-50.2%0.828%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC81,121$0.22M0.0%+53.9%0.171%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.419,997$1.12M0.0%+104.7%0.888%Search for SEC Filing on Google Icon
8/11/2021Susquehanna Fundamental Investments LLC22,094$59K0.0%-47.2%0.047%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC68,574$0.15M0.0%+26.7%0.184%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC91,725$0.20M0.0%+53.8%0.246%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC68,574$0.15M0.0%+26.7%0.184%Search for SEC Filing on Google Icon
5/14/2021Occudo Quantitative Strategies LP29,031$62K0.0%+101.0%0.078%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC786,606$1.68M0.0%+55.3%2.108%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp20,874$45K0.0%+77.0%0.056%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC52,697$0.11M0.0%+99.9%0.141%Search for SEC Filing on Google Icon
4/27/2021Janney Montgomery Scott LLC70,930$0.15M0.0%+13.2%0.190%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC146,128$0.36M0.0%+478.9%0.412%Search for SEC Filing on Google Icon
2/16/2021Squarepoint Ops LLC59,644$0.15M0.0%N/A0.168%Search for SEC Filing on Google Icon
2/12/2021Jaffetilchin Investment Partners LLC11,000$27K0.0%N/A0.031%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC506,389$1.25M0.0%+110.3%1.427%Search for SEC Filing on Google Icon
2/9/2021Pivotal bioVenture Partners Investment Advisor LLC1,180,178$2.92M1.0%N/A3.327%Search for SEC Filing on Google Icon
1/25/2021Janney Montgomery Scott LLC62,663$0.16M0.0%+20.0%0.177%Search for SEC Filing on Google Icon
12/11/2020Virtu Financial LLC25,241$51K0.0%N/A0.071%Search for SEC Filing on Google Icon
11/17/2020Paloma Partners Management Co18,891$39K0.0%N/A0.053%Search for SEC Filing on Google Icon
11/17/2020Jane Street Group LLC20,820$42K0.0%N/A0.059%Search for SEC Filing on Google Icon
11/16/2020Blackstone Group Inc568,004$1.16M0.0%-57.9%1.601%Search for SEC Filing on Google Icon
11/13/2020Sofinnova Investments Inc.1,012,408$2.07M0.2%-14.2%2.854%Search for SEC Filing on Google Icon
11/9/2020Caas Capital Management LP579,379$1.18M0.0%N/A1.633%Search for SEC Filing on Google Icon
11/4/2020Raymond James Financial Services Advisors Inc.34,569$71K0.0%+52.3%0.097%Search for SEC Filing on Google Icon
8/31/2020Bridgeway Capital Management Inc.70,000$0.21M0.0%+100.0%0.256%Search for SEC Filing on Google Icon
8/18/2020Blackstone Group Inc1,350,490$4M0.0%-16.8%4.949%Search for SEC Filing on Google Icon
7/23/2020Janney Montgomery Scott LLC54,898$0.16M0.0%+6.5%0.376%Search for SEC Filing on Google Icon
7/17/2020Raymond James Financial Services Advisors Inc.22,700$67K0.0%+12.4%0.155%Search for SEC Filing on Google Icon
5/13/2020Frazier Management LLC1,049,953$2.78M0.3%-22.2%7.185%Search for SEC Filing on Google Icon
2/13/2020Renaissance Technologies LLC25,300$0.13M0.0%+42.9%0.190%Search for SEC Filing on Google Icon
1/29/2020Eventide Asset Management LLC879,541$4.30M0.1%+124.1%6.617%Search for SEC Filing on Google Icon
11/27/2019Granahan Investment Management Inc. MA141,012$0.84M0.0%+1.8%1.061%Search for SEC Filing on Google Icon
11/27/2019Eventide Asset Management LLC392,513$2.29M0.1%-55.4%2.953%Search for SEC Filing on Google Icon
10/29/2019Janney Montgomery Scott LLC46,861$0.28M0.0%+4.3%0.357%Search for SEC Filing on Google Icon
8/13/2019BlackRock Inc.16,657$0.11M0.0%+29.4%0.127%Search for SEC Filing on Google Icon
8/9/2019Panagora Asset Management Inc.5,987$39K0.0%-27.5%0.046%Search for SEC Filing on Google Icon
7/29/2019Janney Montgomery Scott LLC44,917$0.29M0.0%+5.0%0.342%Search for SEC Filing on Google Icon
2/15/2019Millennium Management LLC34,143$0.14M0.0%-57.0%0.261%Search for SEC Filing on Google Icon
2/13/2019Stifel Financial Corp21,250$86K0.0%-29.2%0.162%Search for SEC Filing on Google Icon
2/8/2019BlackRock Inc.13,755$56K0.0%N/A0.105%Search for SEC Filing on Google Icon
2/1/2019Janney Montgomery Scott LLC41,469$0.17M0.0%N/A0.317%Search for SEC Filing on Google Icon
1/22/2019FNY Investment Advisers LLC13,901$56K0.0%+13,801.0%0.106%Search for SEC Filing on Google Icon
11/15/2018Luminus Management LLC195,750$2.13M0.0%N/A1.498%Search for SEC Filing on Google Icon
11/15/2018Sofinnova Ventures Inc1,180,178$12.84M1.1%N/A9.030%Search for SEC Filing on Google Icon
11/15/2018Hound Partners LLC102,701$1.12M0.0%N/A0.786%Search for SEC Filing on Google Icon
11/13/2018Laurion Capital Management LP50,000$0.54M0.0%N/A0.383%Search for SEC Filing on Google Icon
11/13/2018Credit Suisse AG69,560$0.76M0.0%N/A0.532%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Entasis Therapeutics logo
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
Read More on Entasis Therapeutics

Today's Range

Now: $2.19
Low: $2.19
High: $2.20

50 Day Range

MA: $2.05
Low: $1.75
High: $2.20

52 Week Range

Now: $2.19
Low: $1.40
High: $3.88

Volume

388 shs

Average Volume

243,939 shs

Market Capitalization

$104.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Who are the company insiders with the largest holdings of Entasis Therapeutics?

Entasis Therapeutics' top insider shareholders include:
  1. Elizabeth M Keiley (General Counsel)
  2. Innoviva, Inc (Major Shareholder)
  3. Manoussos Perros (Insider)
Learn More about top insider investors at Entasis Therapeutics.
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.